Zentalis Pharmaceuticals
ZNTL
132 hedge funds and large institutions have $92.9M invested in Zentalis Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 42 increasing their positions, 50 reducing their positions, and 27 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
7% less funds holding
Funds holding: 142 → 132 (-10)
8.99% less ownership
Funds ownership: 90.39% → 81.4% (-9%)
16% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 50
37% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 27
52% less capital invested
Capital invested by funds: $195M → $92.9M (-$102M)
84% less call options, than puts
Call options by funds: $31K | Put options by funds: $188K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.55M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.47M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.23M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.97M |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$13.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.78M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$3.35M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$3.18M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.36M |
ZNTL Hedge Fund Activity: Q1 2025 in Review
132 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2025, worth a combined $92.9M — down 52% from $195M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ZNTL and 17 opened new positions — a net loss of 10 holders — while 50 trimmed existing stakes and 42 added.
The largest buyer was Millennium Management, adding an estimated $4.55M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $13.6M sold.
- 132 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2025, down from 142 in Q4 2024.
- Funds reported $92.9M of Zentalis Pharmaceuticals stock for Q1 2025, down 52% quarter-over-quarter.
- 17 funds opened new Zentalis Pharmaceuticals positions in Q1 2025 and 27 closed out, a net change of -10 holders.
- The largest Zentalis Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $4.55M added.
- The largest Zentalis Pharmaceuticals seller in Q1 2025 was Eventide Asset Management, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2025.